Senzime Management

Management criteria checks 3/4

Senzime's CEO is Philip Siberg, appointed in May 2023, has a tenure of 1.08 years. total yearly compensation is SEK4.61M, comprised of 55.2% salary and 44.8% bonuses, including company stock and options. directly owns 0.59% of the company’s shares, worth €495.26K. The average tenure of the management team and the board of directors is 2.4 years and 3.3 years respectively.

Key information

Philip Siberg

Chief executive officer

kr4.6m

Total compensation

CEO salary percentage	55.2%
CEO tenure	1.1yrs
CEO ownership	0.6%
Management average tenure	2.4yrs
Board average tenure	3.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Philip Siberg's remuneration changed compared to Senzime's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-kr131m
Dec 31 2023	kr5m	kr3m	-kr134m
Sep 30 2023	n/a	n/a	-kr138m
Jun 30 2023	n/a	n/a	-kr137m
Mar 31 2023	n/a	n/a	-kr143m
Dec 31 2022	kr450k	n/a	-kr133m
Sep 30 2022	n/a	n/a	-kr114m
Jun 30 2022	n/a	n/a	-kr104m
Mar 31 2022	n/a	n/a	-kr86m
Dec 31 2021	kr400k	n/a	-kr82m
Sep 30 2021	n/a	n/a	-kr74m
Jun 30 2021	n/a	n/a	-kr66m
Mar 31 2021	n/a	n/a	-kr56m
Dec 31 2020	kr100k	n/a	-kr47m
Sep 30 2020	n/a	n/a	-kr41m
Jun 30 2020	n/a	n/a	-kr36m
Mar 31 2020	n/a	n/a	-kr32m
Dec 31 2019	kr100k	n/a	-kr33m
Sep 30 2019	n/a	n/a	-kr34m
Jun 30 2019	n/a	n/a	-kr33m
Mar 31 2019	n/a	n/a	-kr30m
Dec 31 2018	kr100k	n/a	-kr24m
Sep 30 2018	n/a	n/a	-kr19m
Jun 30 2018	n/a	n/a	-kr16m
Mar 31 2018	n/a	n/a	-kr13m
Dec 31 2017	kr131k	n/a	-kr13m

Compensation vs Market: Philip's total compensation ($USD438.82K) is about average for companies of similar size in the German market ($USD403.64K).

Compensation vs Earnings: Philip's compensation has increased whilst the company is unprofitable.

CEO

Philip Siberg (51 yo)

1.1yrs

Tenure

kr4,614,088

Compensation

Mr. Philip Siberg serves as the Chief Executive Officer of Stille Surgical, Inc. He serves as Chairman of the Board at Acarix AB (publ) since May 11, 2021. He was Co-Founder of Coala-Life Group AB (publ) a...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Philip Siberg	Chief Executive Officer	1.1yrs	kr4.61m	0.59% SEK 505.7k
Slavoljub Grujicic	Chief Financial Officer	2.4yrs	no data	0.021% SEK 17.9k
Johanna Tulkki	Chief Operating Officer	4.4yrs	no data	no data
Fredrik Norrby	Chief Technology Officer	1.4yrs	no data	no data
Rianne Waninge	Application Scientist	no data	no data	no data
Paula Treutiger	Head of Communication & Investor Relations	2.4yrs	no data	no data
Anders Selin	Executive Vice President of Sales	4.8yrs	no data	no data
Michael Noble	Vice President Global Marketing	less than a year	no data	no data
Anders Jacobson	Chief Innovation Officer	8.4yrs	no data	0.013% SEK 11.5k
Catrin Molund	Executive Vice President of Business Development	3.4yrs	kr163.00k	no data
Johanna Faris	Head of Q/RA/S	less than a year	no data	0.0013% SEK 1.1k

2.4yrs

Average Tenure

54yo

Average Age

Experienced Management: 6YC's management team is considered experienced (2.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Per Wold-Olsen	Chairman of the Board	less than a year	no data	0.34% SEK 293.9k
Goran Brorsson	Independent Director	1.1yrs	kr131.00k	0.085% SEK 72.7k
Adam Dahlberg	Vice Chairman of the Board	24.4yrs	kr350.00k	5.25% SEK 4.5m
Eva Walde	Independent Director	3.3yrs	kr210.00k	no data
Sorin Brull	Member of Clinical Advisory Board	8.4yrs	kr1.31m	3.15% SEK 2.7m
Alfredo Abad-Gurumeta	Member of Scientific Advisory Board	no data	no data	no data
Bela Fulesdi	Member of Scientific Advisory Board	no data	no data	no data
Guy Cammu	Member of Scientific Advisory Board	no data	no data	no data
Hans Boer	Member of Scientific Advisory Board	no data	no data	no data
Claude Meistelman	Member of Scientific Advisory Board	no data	no data	no data
Jennifer Hunter	Member of Scientific Advisory Board	no data	no data	no data
Casper Claudius	Member of Scientific Advisory Board	no data	no data	no data

3.3yrs

Average Tenure

68yo

Average Age

Experienced Board: 6YC's board of directors are considered experienced (3.3 years average tenure).

Senzime Management

Management criteria checks 3/4

Key information

Recent management updates

Less than half of directors are independent

Senzime AB (publ) Announces Board Changes

Less than half of directors are independent

Senzime AB (Publ) Appoints Philip Siberg as Chief Executive Officer

Less than half of directors are independent

Independent Chairman recently bought €66k worth of stock

Recent updates

New minor risk - Profitability

Full year 2023 earnings released: kr1.45 loss per share (vs kr1.99 loss in FY 2022)

Senzime AB (publ) to Report Q3, 2024 Results on Nov 06, 2024

Full year 2023 earnings released: kr1.45 loss per share (vs kr1.99 loss in FY 2022)

Less than half of directors are independent

Senzime AB (publ) Announces Board Changes

Senzime Announces New Clinical Study with the Tetragraph System Published in the British Journal of Anesthesia Open

Third quarter 2023 earnings released: kr0.33 loss per share (vs kr0.74 loss in 3Q 2022)

Senzime AB (publ) to Report Fiscal Year 2023 Results on Feb 15, 2024

New major risk - Shareholder dilution

Senzime Launches Tetras Sensitive, the Market's First Sensor for Nemomuscular Monitoring of Patients with Sensitive Skin

No longer forecast to breakeven

Senzime AB (publ) Announces New Study Valued the Feasibility of TetraSens Pediatric Disposable Sensor

Senzime AB (publ) Presents Scientific Study at Euroanaesthesia 2023 and Validates New TetraGraph Electromyographic Detection Algorithm

Less than half of directors are independent

No longer forecast to breakeven

Senzime AB (Publ) Appoints Philip Siberg as Chief Executive Officer

First quarter 2023 earnings released: kr0.42 loss per share (vs kr0.33 loss in 1Q 2022)

Less than half of directors are independent

Independent Chairman recently bought €66k worth of stock

Less than half of directors are independent

Senzime Receives Approval for Its Pediatric Sensor in Japan

Full year 2022 earnings released: kr1.99 loss per share (vs kr1.31 loss in FY 2021)

Senzime AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Senzime AB (publ) to Report Fiscal Year 2022 Results on Feb 01, 2023

Senzime Receives First Contract for TetraSens Pediatric in the US

Less than half of directors are independent

Senzime's TetraGraph supported by new European clinical guidelines for patient monitoring

Senzime AB (publ) Provides Earnings Guidance for 2025

Senzime AB (Publ) Announces Board Appointments

Senzime AB (publ) Receives FDA 510K-Clearance for New Disposable Sensor Intended for Monitoring of Children

Senzime AB (publ) Announces Launch of TetraGraph Xcom Interface to Electronic Medical Records

Forecast breakeven date pushed back to 2024

Second quarter 2022 earnings released: kr0.63 loss per share (vs kr0.35 loss in 2Q 2021)

Less than half of directors are independent

Senzime AB (publ) (OM:SEZI) entered into an agreement to acquire Respiratory Motion, Inc. for $44 million.

First quarter 2022 earnings released: kr0.33 loss per share (vs kr0.27 loss in 1Q 2021)

Less than half of directors are independent

Senzime AB (Publ) Applies for FDA Approval for A New Single-Use Sensor for Children

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Senzime Announces Anesthesia Patient Safety Foundation Recommends Use of A Quantitative Monitor Whenever A Neuromuscular Blocking Agent Is Administered

Senzime AB (Publ) Announces Japanese Study Confirms Tetragraph Monitor as a Better Indicator of Appropriate Reversal Dose of Sugammadex and Adequate Recovery of Neuromuscular Function Than Amg-Based Tof- Watch SX

Third quarter 2021 earnings released: kr0.31 loss per share (vs kr0.20 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.35 loss per share (vs kr0.23 loss in 2Q 2020)

First quarter 2021 earnings released: kr0.27 loss per share (vs kr0.17 loss in 1Q 2020)

Senzime AB (publ) Appoints Eva Walde as New Member of the Board of Directors

Full year 2020 earnings released: kr0.84 loss per share (vs kr0.68 loss in FY 2019)

Senzime AB (publ) to Report Q3, 2021 Results on Nov 12, 2021

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age